Novel vaccine delivers significant survival in lung cancer trial
European Pharmaceutical Review
SEPTEMBER 12, 2023
A T-cell epitope cancer vaccine significantly improved overall survival in non-small cell lung cancer (NSCLC) compared to chemotherapy, Phase III data published in Annals of Oncology has shown. percent with chemotherapy. percent with chemotherapy. The cancer vaccine offered an overall survival of 11.1
Let's personalize your content